Navigation Links
BridgePoint Medical Announces US IDE Approval and First Patient Enrollment of Peripheral Chronic Total Occlusion Study
Date:8/3/2011

MINNEAPOLIS, Aug. 3, 2011 /PRNewswire/ -- BridgePoint Medical, Inc., a Minnesota-based medical device company, has announced that they have enrolled their first patient in the Peripheral Facilitated Antegrade Steering Technique in Chronic Total Occlusions (PFAST-CTOs) study.  The company received approval from the FDA in July, 2011 to move forward with the US based IDE for the peripheral devices and is now actively enrolling patients.  The 10 center, 100 patient U.S. PFAST-CTOs study is designed to assess the safety and effectiveness of the BridgePoint devices in chronically occluded arteries located in the lower extremities.

Dr. Subhash Banerjee of the VA North Texas Health Care System and UT Southwestern Medical Center, the first physician to enroll a patient in the PFAST-CTOs study, stated, "Predicated by the success of the BridgePoint coronary CTO system, we are very optimistic about the Peripheral device's performance possibilities and we are looking forward to a robust and successful study."

The BridgePoint peripheral products are similar to the coronary system in concept, but have been specifically designed and adapted for use in peripheral vasculature and will expand the company's reach into the fast growing peripheral market.  

Company CEO and President Denis Harrington reflected, "This is a very important milestone for BridgePoint Medical. With the IDE approval and the first case enrolled, we are now officially started in our quest to build a strong Peripheral CTO franchise to complement our market leading Coronary CTO franchise."      

About Peripheral Artery Disease and Chronic Total Occlusions:

Atherosclerotic peripheral artery disease (PAD) is a widely prevalent disorder that affects millions world-wide and is associated with significant morbidity and mortality.  A CTO, which represents a complete artery blockage, typically
'/>"/>

SOURCE BridgePoint Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BridgePoint Medical(R) Receives European CE Mark for Stingray(R) and CrossBoss(TM) for Opening Completely Blocked Arteries
2. BridgePoint Medical®, Inc. Completes and Submits to FDA in the U.S. FAST-CTOs With the CrossBoss® and Stingray® CTO Recanalization System
3. BridgePoint Medical Closes $9.1 Million Series C Financing
4. BridgePoint Medical Names Industry Veteran as Chief Executive Officer
5. BridgePoint Medical Announced 510(k) Clearance for an Expanded Indication to Treat Coronary Chronic Total Occlusions
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. Globus Medical Raises $110 Million in Series E Financing Round
10. Quark Pharmaceuticals Appoints New Chief Medical Officer
11. Boston University Biomedical Engineers Find Chink in Bacterias Armor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... VANCOUVER, British Columbia , May 30, 2015 /PRNewswire/ ... today that results from a retrospective analysis of the ... therapy in men with metastatic castrate-resistant prostate cancer (CRPC) ... effect of clusterin inhibition in men at risk for ... in the trial had at least two of five ...
(Date:5/30/2015)... CAMBRIDGE, Massachusetts y SPARTANBURG ... 30, 2015 - Nueva ... clínico terapéutico para pacientes con cáncer en los ... Research Network y Molecular Health proporcionarán a los ...   La Guardian Research Network y ...
(Date:5/30/2015)... , May 30, 2015  Eisai Inc. announced today the ... that eribulin met the study,s primary endpoint evaluating overall survival ... (ADI), two types of advanced soft tissue sarcoma. These data ... of the American Society of Clinical Oncology (ASCO) in ... conference on Saturday, May 30, and also in an oral ...
Breaking Medicine Technology:OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 2OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 3OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 4OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 5OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 6Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 2Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 3Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 2Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 3Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 5Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 6
... 2011 ConvaTec Healthcare, a world-leading developer, manufacturer and ... care, today announced that, following a review of current ... refinancing of its senior secured term loans originally entered ... ConvaTecConvaTec is a leading developer and marketer of innovative ...
... March 17, 2011 Giant Eagle®, the region,s leading ... Association,s (ADA) prestigious Chairman,s Citation Award. Giant ... which recognizes the outstanding accomplishments of individuals, corporations, institutions ... and have had a positive impact in advancing the ...
Cached Medicine Technology:ConvaTec Healthcare Postpones Plans To Refinance Secured Term Loans 2ConvaTec Healthcare Postpones Plans To Refinance Secured Term Loans 3Giant Eagle® Receives American Diabetes Association Chairman's Citation Award 2Giant Eagle® Receives American Diabetes Association Chairman's Citation Award 3
(Date:5/30/2015)... York, New York (PRWEB) May 30, 2015 ... to pay $100 million in punitive and compensatory ... ) plaintiff who suffered serious complications following implantation ... According to a verdict rendered on May 28th ... $25 million in compensatory damages after the jury ...
(Date:5/30/2015)... Belton, Texas (PRWEB) May 30, 2015 ... Client Services Web Portal that gives hospices the ability ... the industry. Because of this business model, EHO has ... offer better pricing to its clients and survive among ... interface with hospice management systems three years ago, it ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 Nicole ... the Disability Income Associate (DIA) designation to further ... DIA designation is designed for insurance advisors, health ... further their knowledge and expertise associated with the ... the DIA designation is only the latest accomplishment ...
(Date:5/30/2015)... 30, 2015 The Brain Fitness Education ... with ONEgeneration Senior Enrichment Center, headed by 1Heart Client ... Guzman and Brain Fitness Program Director Tee Barr. , ... learned that there are many ways to enrich and ... the residents the different ways to overcome dementia and ...
(Date:5/30/2015)... Wixom, Michigan: Proof. Pest Control, a family-owned company ... new twist to its robust line of services-a 100% ... for general pest management. , “We like killing ... Branch Manager. “The average person cringes when they see a ... problems that most people don’t even want to think about. ...
Breaking Medicine News(10 mins):Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Secura Consultants Expands Disability Insurance Expertise 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 3Health News:Proof. Pest Control-Now Offering 100% Organic Pest Control in Southeast Michigan 2
... Dr. Khanna has found PRELEX is better than Lasik for individuals over ... longer lasting, prevents the development of cataracts, and does not induce dry ... ... Dr. Khanna has found PRELEX is better than Lasik for individuals ...
... The Generic Pharmaceutical Association (GPhA) released the following statement ... the nomination of Dr. Margaret Hamburg as Commissioner and ... Food and Drug Administration (FDA)."GPhA stands ready to work ... the Agency as it carries out its mission to ...
... reduce itching, improve quality of life, study finds , , ... Chinese medicine, including tea and acupuncture, may safely and ... finds. , Use of Erka Shizheng Herbal ... months greatly reduced the severity of the itchy, red ...
... with Updated Interoperability Requirements , ... ... -- The Certification Commission for Healthcare Information Technology (CCHIT®) ... 4.0.1 is a CCHIT Certified® 08 Ambulatory EHR meets ...
... Kurzweil , described by Forbes magazine as "the ultimate ... (D-IA), health and wellness expert Dr. Deepak Chopra , ... and Chief Scientific Officer Dr. Mehmood Khan and three ... Race and Reconciliation in America: Health and Wellness for ...
... As a result of the FDA expanding the Peanut Corporation of ... lla related recall to include all peanut ingredient ... Weaver Popcorn Company, Inc. has issued a precautionary voluntary recall for ... , s End (R) Chocolatey Peanut ...
Cached Medicine News:Health News:PRELEX is the Answer for Baby Boomers Vision Needs 2Health News:GPhA Statement on Nomination of Dr. Margaret Hamburg as Commissioner and Dr. Joshua Sharfstein as Deputy Commissioner of FDA 2Health News:Advanced Data System's MedicsDocAssistant™ EHR Receives 08 CCHIT Certification 2Health News:Advanced Data System's MedicsDocAssistant™ EHR Receives 08 CCHIT Certification 3Health News:Chopra, Harkin, Kurzweil, Ornish, Khan Top Race & Reconciliation Conclave on Health and Wellness 2Health News:Chopra, Harkin, Kurzweil, Ornish, Khan Top Race & Reconciliation Conclave on Health and Wellness 3Health News:Chopra, Harkin, Kurzweil, Ornish, Khan Top Race & Reconciliation Conclave on Health and Wellness 4Health News:Weaver Popcorn Company Issues a Nationwide Precautionary Voluntary Recall of 12 oz. (340g) Trail's End(R) Chocolatey Peanut Clusters 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: